Evidence map›Paper›PMID 41001490›Full record

ArticlemedRxiv : the preprint server for health sciences2025

Excitation/inhibition imbalance and conversion to psychosis in the clinical high risk syndrome: Biophysical modeling finds reduced pyramidal cell excitability across EEG paradigms.

Julia Rodriguez-Sanchez, Daniel J Hauke, Dimitris Pinotsis, Lioba C S Berndt, Hope Oloye, Spero C Nicholas, Holly K Hamilton, Brian J Roach, Peter M Bachman, Aysenil Belger and 15 more

Abstract readPreprint
In one paragraph

Article in medRxiv : the preprint server for health sciences, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.

0numbers the graph read from it
0cells of the map it votes in
0citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

0 citing papers in PubMed.

No citing paper in PubMed yet.

4 · The record

Corrections and comments

5 · Who and what money

Authors and funding

25 authors.

Julia Rodriguez-SanchezHawkes Institute, University College London, UK.ORCID 0000-0001-5839-0230
Daniel J HaukeHawkes Institute, University College London, UK.ORCID 0000-0003-1772-9239
Dimitris PinotsisDepartment of Psychology & Neuroscience, City St George's, University of London, UK.ORCID 0000-0002-6865-8103
Lioba C S BerndtHawkes Institute, University College London, UK.ORCID 0009-0006-2455-3031
Hope OloyeHawkes Institute, University College London, UK.
Spero C NicholasMental Health Service, San Francisco Veterans Affairs Health Care System, San Francisco, CA, USA.
Holly K HamiltonMental Health Service, Minneapolis Veterans Affairs Health Care System, Minneapolis, MN, USA.ORCID 0000-0002-4058-0949
Brian J RoachMental Health Service, San Francisco Veterans Affairs Health Care System, San Francisco, CA, USA.ORCID 0000-0002-3264-1465
Peter M BachmanDepartment of Psychiatry, Boston Children's Hospital, Boston, MA, USA.
Aysenil BelgerDepartment of Psychiatry, University of North Carolina at Chapel Hill, Chapel Hill, NC, USA.ORCID 0000-0003-2687-1966
Ricardo E CarriónDivision of Psychiatry Research, The Zucker Hillside Hospital, Northwell Health, Glen Oaks, NY, USA.
Erica DuncanMental Health Service, Atlanta Veterans Affairs Health Care System, Decatur, GA, USA.
Jason K JohannesenDepartment of Psychiatry, Yale University, School of Medicine, New Haven, CT, USA.ORCID 0000-0002-7049-4873
Gregory A LightDepartment of Psychiatry, University of California, San Diego, La Jolla, CA, USA.
Margaret A NiznikiewiczDepartment of Psychiatry, Harvard Medical School at Beth Israel Deaconess Medical Center and Massachusetts General Hospital, Boston, MA, USA.
Karl J FristonWellcome Trust Centre for Neuroimaging, Institute of Neurology, University College London, UK.ORCID 0000-0001-7984-8909
Jean AddingtonHotchkiss Brain Institute Department of Psychiatry, University of Calgary, AB, Canada.
Carrie E BeardenDepartment of Psychiatry and Biobehavioral Sciences, Semel Institute for Neuroscience and Human Behavior, University of California, Los Angeles, CA, USA.ORCID 0000-0002-8516-923X
Kristin S CadenheadDepartment of Psychiatry, University of California, San Diego, La Jolla, CA, USA.ORCID 0000-0002-5952-4605
Diana O PerkinsDepartment of Psychiatry, University of North Carolina at Chapel Hill, Chapel Hill, NC, USA.ORCID 0000-0001-9396-2206
Elaine F WalkerDepartment of Psychiatry and Behavioral Sciences, Emory University School of Medicine, Atlanta, GA, USA.
Scott W WoodsDepartment of Psychiatry, Yale University, School of Medicine, New Haven, CT, USA.ORCID 0000-0002-3103-5228
Tyrone D CannonDepartment of Psychiatry, Yale University, School of Medicine, New Haven, CT, USA.
Rick A AdamsHawkes Institute, University College London, UK.ORCID 0000-0002-7661-8881
Daniel H MathalonDepartment of Psychiatry & Behavioral Sciences, University of California, San Francisco, CA, USA.ORCID 0000-0001-6090-4974

Funding

STRESS AND EMOTIONAL REACTIVITYP50MH066286 · NIMH · UNIVERSITY OF CALIFORNIA LOS ANGELES · PI YEE-BRADBURY, CINDY M. · 2003 to 2014
$18.6M
1/9 Predictors and Mechanisms of Conversion to PsychosisU01MH081902 · NIMH · YALE UNIVERSITY · PI CANNON, TYRONE D · 2008 to 2018
$12.4M
5/9 Predictors and Mechanisms of Conversion to PsychosisU01MH082004 · NIMH · UNIV OF NORTH CAROLINA CHAPEL HILL · PI PERKINS, DIANA O. · 2008 to 2018
$7.5M
Administrative Supplement Harmonization of At Risk Multisite Observational Networks for Youth(HARMONY)U01MH081928 · NIMH · BETH ISRAEL DEACONESS MEDICAL CENTER · PI STONE, WILLIAM SETH · 2008 to 2018
$7.1M
4/9-Predictors and Mechanisms of Conversion to PsychosisU01MH081857 · NIMH · FEINSTEIN INSTITUTE FOR MEDICAL RESEARCH · PI CORNBLATT, BARBARA A. · 2008 to 2018
$6.2M
8/9 Predictors and Mechanisms of Conversion to PsychosisU01MH082022 · NIMH · YALE UNIVERSITY · PI WOODS, SCOTT W · 2008 to 2018
$6.0M
2/9 - Predictors and Mechanisms of Conversion to PsychosisU01MH081988 · NIMH · EMORY UNIVERSITY · PI WALKER, ELAINE FRAN · 2008 to 2018
$5.4M
6/9-Predictors and Mechanisms of Conversion to PsychosisU01MH081944 · NIMH · UNIVERSITY OF CALIFORNIA, SAN DIEGO · PI CADENHEAD, KRISTIN S. · 2008 to 2018
$4.9M
"7/9" Predictors and Mechanisms of Conversion to PsychosisU01MH081984 · NIMH · UNIVERSITY OF CALGARY · PI ADDINGTON, JEAN M · 2008 to 2018
$4.2M
9/9-Predictors and Mechanisms of Conversion to PsychosisU01MH076989 · NIMH · NORTHERN CALIFORNIA INSTITUTE/RES/EDU · PI MATHALON, DANIEL H · 2014 to 2018
$3.9M
NIMH NIH HHS P50 MH066286NIMH NIH HHS U01 MH076989NIMH NIH HHS U01 MH081857NIMH NIH HHS U01 MH081902NIMH NIH HHS U01 MH081928NIMH NIH HHS U01 MH081944NIMH NIH HHS U01 MH081984NIMH NIH HHS U01 MH081988NIMH NIH HHS U01 MH082004NIMH NIH HHS U01 MH082022Wellcome Trust
6 · The paper itself

Abstract

Background: Reduced mismatch negativity (MMN) and P300 event-related potential (ERP) components are widely replicated in schizophrenia and are also observed in individuals at clinical high risk for psychosis (CHR-P) who subsequently convert to psychosis. It is unknown whether they reflect changes in excitatory and/or inhibitory synaptic function, both implicated in schizophrenia and considered potential drug targets. Methods: We analyzed baseline MMN and P300 ERPs from the NAPLS2 study, asking whether altered synaptic excitation, inhibition, or both could explain amplitude reductions in CHR-P (n=583). CHR-P participants who converted to psychosis (CHR-Converters; n=77) or remitted by 24-month follow-up (CHR-Remitters; n=94) were compared on MMN evoked by pitch+duration double-deviant tones and P300 elicited by target tones from passive and active auditory oddball paradigms, respectively. Biophysical modeling was used to infer (excitatory) pyramidal cell and (inhibitory) interneuron function from both MMN and P300 ERPs. Results: MMN and P300 amplitude reductions in future CHR-Converters relative to CHR-Remitters were best explained by reduced pyramidal cell excitability (posterior probability P>.95 of a group-by-condition interaction effect). In simulations, reduced pyramidal cell excitability suppressed deviant and target ERPs. Within CHR-Converters, but not CHR-Remitters, more severe positive symptoms were associated with disinhibition of pyramidal cells (P>.99). Conclusions: Results mirror previous findings in schizophrenia and suggest that reduced pyramidal cell excitability is present at baseline in future CHR-Converters, supporting the hypothesis that hypofunction of pyramidal cells is a primary pathology in schizophrenia, rather than a consequence of chronic illness. Positive symptoms among CHR-Converters may reflect compensatory downregulation of inhibition.

Indexed as

biophysical modelingClinical high risk for psychosisdynamic causal modelingE/I balanceMMNP300

Identifiers

PMID41001490
PMCPMC12458603

What OpenQuestion holds

Textmetadata
LicenceCC BY-NC
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.